tiprankstipranks
Natera Inc. (NTRA)
NASDAQ:NTRA
Want to see NTRA full AI Analyst Report?

Natera (NTRA) Price & Analysis

1,228 Followers

NTRA Stock Chart & Stats

$208.40
$1.33(0.78%)
At close: 4:00 PM EST
$208.40
$1.33(0.78%)

Bulls Say, Bears Say

Bulls Say
Improved Cash GenerationNatera’s transition to positive operating cash flow and meaningful free cash flow provides durable funding for R&D, trial enrollment, and commercial scaling without immediate reliance on equity markets. That cash cushion reduces refinancing risk and supports multi‑quarter investment in oncology rollouts.
Conservative Balance SheetLow leverage and a sizable equity base give Natera flexibility to fund growth initiatives, absorb temporary reimbursement delays, and execute strategic investments or tuck‑ins. A conservative balance sheet materially enhances financial resilience across 2–6 month horizons.
Signatera Scale & Clinical MomentumRapid and large‑scale adoption of Signatera creates durable unit economics and network effects; rising volumes, supportive clinical publications and planned geographic expansion (Japan PMDA path) strengthen long‑term TAM, pricing leverage and payer negotiation position.
Bears Say
Ongoing Net LossesDespite strong revenue and gross margins, continued operating losses limit returns and keep ROE negative. If profitability does not convert sustainably, ongoing losses could force tradeoffs between growth spending and margin improvement, constraining durable shareholder value creation.
Payer Coverage & Prior‑auth FrictionSignificant reliance on reimbursement expansion makes revenues sensitive to payer decisions. Prior authorization and MolDx coverage gaps can materially slow test uptake, delay cash collection and increase sales effort costs, creating a persistent headwind to predictable revenue growth.
Dependence On Clinical/regulatory MilestonesFuture revenue expansion hinges on successful trial outcomes and PMA approvals (e.g., FIND CRC) and scaling new product launches. Delays, negative readouts or slower commercialization would materially slow TAM capture and extend timelines to meaningful revenue contribution.

Natera News

NTRA FAQ

What was Natera Inc.’s price range in the past 12 months?
Natera Inc. lowest stock price was $131.81 and its highest was $256.36 in the past 12 months.
    What is Natera Inc.’s market cap?
    Natera Inc.’s market cap is $33.14B.
      When is Natera Inc.’s upcoming earnings report date?
      Natera Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 39 days.
        How were Natera Inc.’s earnings last quarter?
        Natera Inc. released its earnings results on May 07, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.542 by -$0.058.
          Is Natera Inc. overvalued?
          According to Wall Street analysts Natera Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Natera Inc. pay dividends?
            Natera Inc. does not currently pay dividends.
            What is Natera Inc.’s EPS estimate?
            Natera Inc.’s EPS estimate is -0.49.
              How many shares outstanding does Natera Inc. have?
              Natera Inc. has 143,215,380 shares outstanding.
                What happened to Natera Inc.’s price movement after its last earnings report?
                Natera Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.542. Following the earnings report the stock price went down -11.637%.
                  Which hedge fund is a major shareholder of Natera Inc.?
                  Currently, no hedge funds are holding shares in NTRA
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Natera Inc.

                    Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

                    Natera (NTRA) Earnings & Revenues

                    NTRA Company Deck

                    NTRA Earnings Call

                    Q1 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call conveyed strong, broad-based operational momentum—robust revenue and unit growth (Q1 revenue $697M, +39% YoY), record oncology volumes (249k MRD tests, +55% YoY), successful new-product launches (Fetal Focus approaching ~200k annualized orders), improved ASPs (Signatera ~$1,250) and raised guidance (revenue guide midpoint reset up >$120M; gross margin guidance to 65% midpoint). Transient headwinds (work-in-process timing, acquisition-related COGS, temporary DSO impact, weather effects, and some coverage/authorization friction) were identified but characterized as short-term or manageable. Given the magnitude and number of positive operational and financial developments and management's upward guide and investment posture, the highlights materially outweigh the lowlights.View all NTRA earnings summaries

                    NTRA Stock 12 Month Forecast

                    Average Price Target

                    $264.92
                    ▲(27.12% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"133":"$133","175":"$175","217":"$217","259":"$259","301":"$301"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$300.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":264.9230769230769,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$264.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$220.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[133,175,217,259,301],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,218.81,225.0553846153846,231.30076923076922,237.54615384615386,243.79153846153847,250.03692307692307,256.2823076923077,262.5276923076923,268.7730769230769,275.01846153846157,281.26384615384615,287.5092307692308,293.75461538461536,{"y":300,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,218.81,222.3571597633136,225.9043195266272,229.45147928994083,232.99863905325444,236.54579881656804,240.09295857988164,243.64011834319527,247.18727810650887,250.73443786982247,254.28159763313607,257.8287573964497,261.3759171597633,{"y":264.9230769230769,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,218.81,218.90153846153845,218.99307692307693,219.08461538461538,219.17615384615385,219.2676923076923,219.35923076923078,219.45076923076923,219.5423076923077,219.63384615384615,219.72538461538463,219.81692307692308,219.90846153846155,{"y":220,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":160.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.58,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":169.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.93,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":234.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":229.09,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":231.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.17,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.21,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.28,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":218.81,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Illumina
                    NeoGenomics
                    Fulgent Genetics
                    Guardant Health

                    Ownership Overview

                    3.09%34.23%26.60%19.83%
                    26.60% Other Institutional Investors
                    19.83% Public Companies and
                    Individual Investors
                    Popular Stocks